A protein may help brain tumor cells survive chemo
Original title: SLMO2 Promotes Chemoresistance in Glioblastoma by Regulating BNIP3-Dependent Mitophagy via the NF-κB/HIF-1α Axis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done with cells in the lab, not in people.
The short version
In lab tests, blocking one protein made brain tumor cells easier to kill with chemo.
What was studied. Researchers worked with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells in the lab. They lowered a protein called SLMO2, then treated the cells with the chemo drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary.
What they found. Low-dose chemo made the cells clear out damaged parts inside themselves. That clean-up appeared to protect the cells and keep them alive. When the team lowered SLMO2, that defense broke down and more cells died from the chemo. The same pattern showed up with a second chemo drug, cisplatin.
What this means, and what it doesn't
What it could mean: It points to a possible new way to make chemo work better in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. For now it is a target for future drug research. Nothing here changes treatment today.
What it doesn't mean: This was done with cells in a dish, not in people. No drug that blocks this protein is available to patients. We do not know yet if it is safe or helpful in humans. This is not a cure and not a promise of one. Much more research would be needed first.
Source: PubMed, October 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.